Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
| ▸ | RBP4 | P02753 | 1/20 | 0.35 |
| ▸ | F2R | P25116 | 4/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 3/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.32 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.31 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.31 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.31 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.30 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.30 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16947094 | 1.00 | AAK1 (0.37) | AAK1RBP4F2RPDK2HTR2C | |
| SCHEMBL19631449 | 0.89 | AAK1 (0.34) | AAK1RBP4 | |
| SCHEMBL16947089 | 0.82 | KDM4E (0.39) | F2RTGFBR1TGFBR2ALKMKNK1 | |
| SCHEMBL18352908 | 0.82 | KDM4E (0.39) | F2RTGFBR1TGFBR2ALKMKNK1 | |
| SCHEMBL18352379 | 0.79 | SCN9A (0.40) | AAK1F2RPDK2TGFBR1MKNK1 | |
| SCHEMBL16947088 | 0.79 | RBP4 (0.39) | RBP4 | |
| SCHEMBL16935982 | 0.76 | SCN9A (0.38) | AAK1F2RTGFBR1MKNK1 | |
| SCHEMBL30092492 | 0.76 | SCN9A (0.38) | AAK1F2RTGFBR1MKNK1 | |
| SCHEMBL18357995 | 0.76 | RBP4 (0.33) | RBP4PDK2HTR2CSLC6A4HTR2A | |
| SCHEMBL16946750 | 0.75 | NTRK1 (0.37) | RBP4PDK2P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9714258-B2 | Diaryl macrocycles as modulators of protein kinases | TP THERAPEUTICS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-9714258-B2 | Diaryl macrocycles as modulators of protein kinases | TP THERAPEUTICS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20170002023-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | TP THERAPEUTICS, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| US-20170002023-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | TP THERAPEUTICS, INC. (US) | 2017-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170002023-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | MAP3K20, LCK, MAP3K1 | AAK1 86/4885RBP4 4739/4885F2R 1952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.